Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$595.30 USD
-1.85 (-0.31%)
Updated May 17, 2024 04:00 PM ET
After-Market: $595.32 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
TMO 595.30 -1.85(-0.31%)
Will TMO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TMO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TMO
Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array
Don't Overlook Thermo Fisher (TMO) International Revenue Trends While Assessing the Stock
TMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Thermo Fisher Scientific, Disney, Southern Copper, Tractor Supply and Omnicom
Top Research Reports for Thermo Fisher Scientific, Walt Disney & Southern Copper
Company News for Apr 25, 2024
Other News for TMO
3 Best Non-Nvidia AI Stocks to Buy in May 2024, as per Analysts
Least shorted S&P 500 stocks as a percentage of float
Short interest in S&P 500 healthcare sector dips in April, biotechnology companies most shorted
Buy Rating Affirmed for Thermo Fisher on Strong Market Position and Solid Growth Prospects
Galapagos, BCA to collaborate on CAR-T cell therapy production